Abstracts Archive - Page 937 of 2607 - ACR Meeting Abstracts

Abstract Number: 1509 • ACR Convergence 2020
Leukocyte Telomere Length and Childhood Onset of Systemic Lupus Erythematosus in the Black Women’s Experiences Living with Lupus (BeWELL) Study
John Bridges¹, Kara Chung², Connor Martz², Emily Smitherman¹, Cristina Drenkard³, S. Sam Lim⁴ and David Chae², ¹University of Alabama at Birmingham, Birmingham, AL, ²Auburn University, Auburn, AL, ³Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA, ⁴Emory University, Atlanta, GA
Background/Purpose: Childhood-onset SLE is generally more aggressive than adult-onset SLE. Leukocyte telomere length (LTL) has been posited to reflect immune system aging. Short LTL in…
Abstract Number: 1510 • ACR Convergence 2020
Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
Yevgeniya Gartshteyn¹, Adam Mor², Daichi Shimbo², Leila Khalili³, Teja Kapoor⁴, Laura Geraldino-Pardilla⁵, Roberta Vezza Alexander⁶, Thierry Dervieux⁷ and Anca Askanase², ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University Medical Center, New Haven, CT, ⁴Columbia University College of Physicians and Surgeons, Leonia, NJ, ⁵Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, ⁶Exagen Inc, Vista, CA, ⁷Prometheus Biosciences Inc, Irvine, CA
Background/Purpose: Platelets have a well-defined role in arterial thrombosis, and platelet-bound complement activation products (PC4d) correlate with vascular thromboses in patients with Systemic Lupus Erythematosus…
Abstract Number: 1511 • ACR Convergence 2020
Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Melissa Munroe¹, Kendra Young², Jill Norris³, Joel Guthridge⁴, Diane Kamen⁵, Timothy Niewold⁶, Gary Gilkeson⁷, Michael Weisman⁸, Mariko Ishimori⁹, Daniel Wallace¹⁰, David Karp¹¹, John Harley¹² and Judith James¹³, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²University of Colorado Denver, Aurora, CO, ³Colorado School of Public Health, Aurora, CO, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Medical University of South Carolina, Charleston, SC, ⁶NYU School of Medicine, New York, NY, ⁷Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹¹UT Southwestern Medical Center, Dallas, TX, ¹²Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Unaffected blood relatives (BRs) of lupus…
Abstract Number: 1512 • ACR Convergence 2020
Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis
Andrea Fava¹, Avi Rosenberg², Serena Bagnasco², Paride Fenaroli², Jessica Li¹, Jose Monroy-Trujillo², Derek Fine² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this…
Abstract Number: 1513 • ACR Convergence 2020
Role of Platelet C4d in Thrombosis and Lupus Nephritis
Michelle Petri¹, Jessica Li², John Conklin³, Tyler O'Malley⁴, Jo-Anne Ligayon⁵, Leilani Wolover⁵ and Thierry Dervieux⁶, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³Exagen Inc., Vista, CA, ⁴Exagen, Inc, San Diego, CA, ⁵Exagen Diagnostics, San Diego, CA, ⁶Prometheus Biosciences, Inc. (former employee of Exagen Diagnostics), Irvine, CA
Background/Purpose: The SLE thrombosis risk equation contains three components: lupus anticoagulant (dRVVT), low C3 and C4d bound to platelets (platelet C4d). We examined the role…
Abstract Number: 1514 • ACR Convergence 2020
The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study
April Jorge¹, Xiaoqing Fu², Yuqing Zhang³, Hyon Choi⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Harvard Medical School, Boston, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁵Harvard Medical School, Boston
Background/Purpose:A major complication of systemic lupus erythematosus (SLE) is the progression of lupus nephritis (LN) to end-stage kidney disease (ESKD). Both SLE and ESKD are…
Abstract Number: 1515 • ACR Convergence 2020
Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort
Philip Carlucci¹, Andrea Fava², Kristina Deonaraine¹, Jessica Li³, David Wofsy⁴, Judith James⁵, Chaim Putterman⁶, Betty Diamond⁷, Derek Fine⁸, Jose Monroy-Trujillo⁸, Kristin Haag⁸, William Apruzzese⁹, H. Michael Belmont¹⁰, Peter Izmirly¹¹, Sean Connery¹², Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Partnership in SLE Network¹⁹, Michelle Petri²⁰ and Jill Buyon²¹, ¹New York University School of Medicine, New York, ²Johns Hopkins, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Northwell Health, Hartford, ⁸Johns Hopkins University, Baltimore, ⁹., Boston, ¹⁰NYU School of Medicine, New York, NY, ¹¹Department of Medicine, New York University School of Medicine, New York, NY, ¹²Texas Tech University Health Sciences Center, Lubbock, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶University of California San Francisco, San Francisco, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸School of Health Sciences, University of California, La Jolla, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Poor therapeutic response rates contribute to the increased morbidity and mortality associated with lupus nephritis. Early identification of patients likely to respond is crucial…
Abstract Number: 1516 • ACR Convergence 2020
The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership
Philip Carlucci¹, Kristina Deonaraine¹, Andrea Fava², Jessica Li³, David Wofsy⁴, Judith James⁵, Chaim Putterman⁶, Betty Diamond⁷, Derek Fine⁸, Jose Monroy-Trujillo⁸, Kristin Haag⁸, William Apruzzese⁹, H. Michael Belmont¹⁰, Peter Izmirly¹¹, Sean Connery¹², Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Partnership in SLE Network¹⁹, Michelle Petri²⁰ and Jill Buyon²¹, ¹New York University School of Medicine, New York, ²Johns Hopkins, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Northwell Health, Hartford, ⁸Johns Hopkins University, Baltimore, ⁹., Boston, ¹⁰NYU School of Medicine, New York, NY, ¹¹Department of Medicine, New York University School of Medicine, New York, NY, ¹²Texas Tech University Health Sciences Center, Lubbock, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶University of California San Francisco, San Francisco, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸School of Health Sciences, University of California, La Jolla, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with…
Abstract Number: 1517 • ACR Convergence 2020
Metabolic Regulation of Type 3 Innate Lymphoid Cells by Intestinal Bacteria-Derived Indoles in Ankylosing Spondylitis
Adam Berlinberg¹, Adam Lefferts², Emilie Regner³, Andrew Stahly⁴ and Kristine Kuhn⁴, ¹University of Colorado, Denver, CO, ²University of Colorado, Anschutz Medical Campus, Denver, CO, ³University of California San Francisco, San Francisco, CA, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Intestinal microbial dysbiosis, intestinal inflammation, and Th17 immunity are all linked to the pathophysiology of ankylosing spondylitis (AS); however, the mechanisms linking them remain…
Abstract Number: 1518 • ACR Convergence 2020
The Role for Neutrophils in the Early Phases of Enthesitis in Spondyloarthritis
Zheni Stavre¹, Charles Bridgewood², Qiao Zhou², Yukiko Maeda³, Jozsef Karman⁴, Dennis McGonagle⁵ and Ellen Gravallese⁶, ¹University of Massachusetts Medical School-Rheumatology Division, Worcester, MA, ²University of Leeds, Leeds, United Kingdom, ³University of Massachusetts Medical School, worcester, MA, ⁴Abbvie Inc., Worcester, MA, ⁵The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Neutrophils are present in the early phases of spondyloarthritis (SpA)-associated uveitis, skin and intestinal disease, but their role in enthesitis remains unknown. We investigated…
Abstract Number: 1519 • ACR Convergence 2020
Interleukin-17D, a Cytokine Derived from Stromal Cells, Attenuates Joint Inflammation
Sijia Chen¹, Catherine Manning², Melissa van Tok³, Yukiko Maeda⁴, Daniel Montoro⁵, Jung-Min Kim⁶, Jeroen den Dunnen³, Nataliya Yeremenko³, Jae-Hyuck Shim⁴, Dominique Baeten⁷ and Ellen Gravallese⁸, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women’s Hospital, Boston, ³Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴University of Massachusetts Medical School, worcester, MA, ⁵Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, ⁶University of Massachusetts Medical School, Worcester, ⁷UCB Pharma / Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: Interleukin(IL)-17D is a little recognized member of the IL-17 family of cytokines. While the activities of IL-17A and IL-17F in the pathogenesis of spondyloarthritis…
Abstract Number: 1520 • ACR Convergence 2020
Characterisation of Rheumatoid and Psoriatic Arthritis Synovial Fibroblasts
Clare Cunningham¹, Sharon Ansboro¹, Sarah Wade¹, Candice Low², Ronan Mullan³, Douglas Veale⁴ and Ursula Fearon⁵, ¹Trinity College Dublin, Dublin, Ireland, ²EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, ³Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁴EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ⁵Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland
Background/Purpose: The synovial inflammation observed in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) is characterised by synovial fibroblast hyperplasia, leukocyte infiltration, neoangiogenesis and hypoxia. These…
Abstract Number: 1521 • ACR Convergence 2020
A Novel Gut-joint Migratory TCRab+ Cell Subset Relies on sphingosine-1-phosphate for Tissue Localization
Adam Lefferts¹, Emilie Regner², Eric Norman³, David Claypool⁴, Hannah Schultz⁴, Danielle Sansone-Poe⁴ and Kristine Kuhn⁵, ¹University of Colorado, Anschutz Medical Campus, Aurora, CO, ²University of California San Francisco, San Francisco, CA, ³University of Colorado, Anschutz Medical Campus, Denver, ⁴University of Colorado, Anschutz Medical Campus, Aurora, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Despite findings of similar immune cellular phenotypes in the gut and joint of patients with spondyloarthritis, the mechanistic linkage between intestinal immunology and the…
Abstract Number: 1522 • ACR Convergence 2020
Biomarkers of Hemodynamic Severity of Systemic-Sclerosis Associated Pulmonary Arterial Hypertension by Serum Proteome Analysis
Sebastien Sanges¹, Lisa Rice², Ly Tu³, Jean-Luc Cracowski⁴, David Montani⁵, Julio Mantero⁶, Camille Ternynck⁷, Guillemette Marot⁷, Eric Hachulla⁸, David Launay⁹, Marc Humbert⁵, Christophe Guignabert⁵ and Robert Lafyatis¹⁰, ¹Medecine Interne CHRU Lille, Lille, France, ²E5 Arthritis Center, Boston, MA, ³INSERM U1286, Le Kremlin Bicetre, France, ⁴Univ. Grenoble Alpes, INSERM, HP2, Grenoble, France, ⁵INSERM U999 "Pulmonary hypertension: Pathophysiology and Novel Therapies", Le Kremlin-Bicêtre, France, ⁶Boston University School of Medicine, E5 Arthritis Center, Boston, ⁷Univ. Lille, CHU Lille, ULR2694 – METRICS, Lille, France, ⁸Department of Internal Medicine, CHRU, Lille Cedex, France, ⁹Medecine Interne CHRU Lille, Lille Cedex, France, ¹⁰University of Pittsburgh, Pittsburgh, PA
Background/Purpose: To investigate alterations in the serum proteome of patients with systemic sclerosis (SSc)-associated pulmonary hypertension (PAH), to identify proteins that correlated with hemodynamic severity…
Abstract Number: 1523 • ACR Convergence 2020
Pulmonary Cytokine, Chemokine and Growth Factor Profiles of Distinct Radiographic Patterns of Interstitial Lung Disease in Systemic Sclerosis
Elizabeth Volkmann¹, Donald Tashkin², Ning Li², Mei Leng², Grace Kim², Jonathan Goldin², Airi Harui² and Michael Roth², ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles
Background/Purpose: The radiological hallmarks of systemic sclerosis-related interstitial lung disease (SSc-ILD) include interstitial inflammation (ground glass opacity) with reticular changes (fibrosis). The precise pathobiology of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].